Clinical trials are research studies conducted in human volunteers in an attempt to determine if an investigational drug or treatment is safe and provides a benefit to patients. These studies allow researchers and doctors to learn about a compound's activity and side effects, as well as to explore possible indications for a new drug or combinations of drugs. Data from a clinical trial help to increase knowledge about a specific disease and its potential treatment. For general information about clinical trial participation, please visit the National Institutes of Health (NIH) website.

Onyx, together with our collaborator, Bayer Pharmaceuticals, is supporting a number of clinical trials of Nexavar® (sorafenib) tablets -- both as a single agent and in combination with other anticancer agents -- in a range of tumor types. Nexavar is being evaluated in multiple clinical trials ranging from Phase 1, Phase 2, or Phase 3 clinical trials in kidney, skin, liver, lung, breast, and other cancers. For more information on studies that are currently enrolling patients, please select one of the tabs on the left, or visit clinicaltrials.gov.

Nexavar is approved in the U.S. (view press release) and the EU (view press release) for the treatment of patients with advanced kidney cancer, as well as in the U.S. (view press release) and in the EU (view press release) for treatement of patients with liver cancer.